List of Excipients in Branded Drug TEMBEXA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Emergent BioDefense Operations Lansing LLC	TEMBEXA	brincidofovir	64678-010	CELLULOSE, MICROCRYSTALLINE	2028-06-04
Emergent BioDefense Operations Lansing LLC	TEMBEXA	brincidofovir	64678-010	CROSPOVIDONE	2028-06-04
Emergent BioDefense Operations Lansing LLC	TEMBEXA	brincidofovir	64678-010	FD&C BLUE NO. 1	2028-06-04
Emergent BioDefense Operations Lansing LLC	TEMBEXA	brincidofovir	64678-010	FD&C BLUE NO. 2	2028-06-04

Tembexa Excipient Strategy and Commercial Opportunities

Last updated: August 6, 2026

Tembexa, the oral brincidofovir product approved for smallpox, has a differentiated excipient opportunity centered on pediatric usability, long-term stockpile stability, simplified logistics, and formulation IP. Its two dosage forms, 100 mg tablets and 10 mg/mL oral suspension, address adult and pediatric administration but create separate commercial requirements. The most attractive opportunities are taste-masked liquid formulations, room-temperature-stable presentations, low-volume dosing systems, and excipient packages designed for government stockpiles rather than routine retail distribution.

Executive summary

• Tembexa contains brincidofovir, a lipid-conjugated antiviral approved by the FDA in 2021 for treatment of human smallpox caused by variola virus in adults and pediatric patients, including neonates.
• The product has tablets and an oral suspension. The suspension is commercially important because pediatric dosing is weight-based and can be difficult to deliver with a solid dosage form.
• Excipient value is concentrated in taste masking, suspension stability, microbial control, dose uniformity, redispersibility, and long-term storage.
• Tembexa is a small-molecule drug. Biosimilar pathways do not apply, although generic applicants could pursue ANDA approval if they can establish pharmaceutical equivalence and satisfy applicable patent certifications.
• The main commercial buyer is the U.S. government and strategic national-security stockpiles, not the conventional retail pharmacy market.
• Excipient suppliers can pursue opportunities through qualified replacement excipients, pediatric formulation upgrades, dosing devices, packaging systems, and contract manufacturing partnerships.
• The strongest IP barriers are likely to relate to brincidofovir composition, formulations, manufacturing, and therapeutic use. An excipient substitution alone may avoid one formulation claim but does not necessarily avoid broader drug or method-of-use patents.

What is Tembexa and how does its formulation create excipient demand?

Tembexa is an oral formulation of brincidofovir, also known as CMX001. Brincidofovir is a lipid-conjugated derivative of cidofovir developed to improve oral delivery and reduce some limitations associated with intravenous cidofovir. The FDA approved Tembexa under the Animal Rule because human efficacy trials for smallpox are not feasible or ethical. Safety and pharmacokinetic evidence supported approval in combination with animal efficacy data (FDA, 2021a).

The product has two presentations:

Presentation	Strength	Primary use case	Excipient priorities
Film-coated tablet	100 mg	Adults and patients able to swallow tablets	Compression, coating, dissolution, stability
Oral suspension	10 mg/mL	Pediatric patients and patients unable to swallow tablets	Taste masking, suspension stability, dose uniformity, microbial preservation

The suspension has greater formulation complexity. Brincidofovir is a lipophilic molecule, so the formulation must maintain consistent dispersion and dose delivery during storage and administration. Pediatric patients may reject a formulation with strong bitterness, lipid-related mouthfeel, or aftertaste. A commercially useful excipient platform must address palatability without compromising chemical stability or bioavailability.

What excipients are used in Tembexa?

The FDA prescribing information identifies different inactive-ingredient systems for the tablet and suspension. The tablet contains conventional pharmaceutical excipients used for direct compression, coating, flow, lubrication, and physical integrity. The oral suspension contains excipients associated with aqueous dispersion, pH control, preservation, chelation, and palatability.

Public labeling identifies excipient classes including:

Formulation function	Tembexa excipient examples identified in FDA labeling
Tablet filler and compression aid	Microcrystalline cellulose, lactose monohydrate
Tablet disintegration	Croscarmellose sodium
Lubrication	Magnesium stearate
Coating and appearance	Hypromellose, polyvinyl alcohol, talc, titanium dioxide
Surfactant or wetting support	Sodium lauryl sulfate
Suspension vehicle and pH control	Citric acid and citrate salts
Preservation	Sodium benzoate
Chelation and metal-ion control	Disodium edetate
Wetting and dispersion	Polysorbate 80
Sweetening and palatability	Sucrose and flavoring components

The exact commercial opportunity depends on the approved product's qualitative and quantitative composition, manufacturing process, packaging configuration, and regulatory comparability requirements. A supplier that proposes a replacement excipient must demonstrate that the change does not alter critical quality attributes, including assay, impurities, particle-size distribution, redispersibility, dissolution, microbial quality, and dose uniformity.

What excipient strategy is most important for Tembexa oral suspension?

The central strategy is a pediatric-ready suspension platform with four performance targets: palatability, physical stability, microbiological control, and dosing accuracy.

Taste masking and pediatric acceptability

Brincidofovir is a lipophilic antiviral with formulation characteristics that can create bitterness or an oily oral sensation. The current suspension uses a multi-excipient approach rather than relying on a single sweetener. Commercial development could focus on:

• Flavor systems compatible with aldehyde-sensitive or lipid-containing drugs.
• Ion-exchange resins or polymeric taste-masking systems.
• Coacervates or microencapsulation that reduce direct contact with taste receptors.
• Lower-sugar systems for patients with metabolic or dietary restrictions.
• Flavor profiles optimized for neonates, infants, and older children.
• Sweetener combinations that minimize excessive sucrose exposure.

A taste-masking change would have to preserve brincidofovir release and absorption. Strong binding between the drug and a resin or polymer could reduce bioavailability and create a regulatory comparability problem.

Suspension stability and redispersibility

A stockpiled suspension must remain physically uniform after prolonged storage and repeated handling. Key formulation variables include:

• Sedimentation rate.
• Ease of redispersion after storage.
• Particle-size distribution.
• Viscosity across temperature ranges.
• Adsorption to the container or dosing syringe.
• Compatibility with high-density polyethylene bottles and elastomeric closures.

Polymeric suspending agents could improve dose uniformity but may increase viscosity and make oral syringe withdrawal difficult. A low-viscosity, rapidly redispersible system is better suited to emergency deployment, particularly when caregivers or healthcare workers may have limited preparation time.

Preservative and microbial control

Sodium benzoate and related preservation systems are commercially relevant because Tembexa suspension is an aqueous multidose product. Pediatric use requires careful control of preservative exposure, especially in neonates and young infants. A preservative strategy must consider:

• pH-dependent preservative efficacy.
• Container-closure integrity.
• In-use stability after opening.
• Compatibility with dosing syringes.
• Microbial challenge performance.
• Regulatory limits for pediatric exposure.

An alternative preservative system could create value if it extends in-use stability, reduces preservative concentration, or improves compatibility with a revised container. The change would require comprehensive microbial and stability studies.

What commercial opportunities exist for Tembexa excipient suppliers?

The highest-value opportunities are linked to procurement reliability and emergency-use performance rather than ordinary prescription volume.

Stockpile-oriented packaging and formulation

Tembexa is relevant to government preparedness programs, including the Strategic National Stockpile. A commercial excipient or packaging partner can create value by supporting:

• Long shelf life at controlled room temperature.
• Reduced cold-chain dependence.
• Low-volume bottles for pediatric dosing.
• Unit-dose or multi-dose configurations.
• Tamper-evident and child-resistant packaging.
• Integrated oral syringes with verified dose markings.
• Secondary packaging resistant to humidity and temperature excursions.

For a stockpile product, supply continuity matters. Manufacturers may qualify a second source for surfactants, preservatives, flavors, or polymers to reduce single-supplier risk.

Pediatric reformulation

A next-generation Tembexa suspension could target easier administration and lower dosing error. Product concepts include:

1. A concentrated suspension requiring a smaller administered volume.
2. A ready-to-use product that eliminates reconstitution.
3. A powder-for-suspension presentation with superior shelf life.
4. A unit-dose oral syringe or sachet system.
5. A sugar-reduced or sugar-free liquid.
6. A formulation with improved taste masking and reduced aftertaste.

The commercial case is strongest for a product that materially improves emergency pediatric administration while preserving the existing dosing algorithm.

Alternative solid dosage forms

Patients unable to swallow tablets create demand for additional dosage forms. Potential platforms include:

• Multiparticulates in sprinkle capsules.
• Mini-tablets.
• Orally disintegrating tablets.
• Oral granules.
• Buccal or dispersible dosage forms.

These products would need to address brincidofovir's dose, lipid character, dissolution behavior, and taste. A multiparticulate product could be useful for pediatric patients who can consume soft food but cannot swallow a tablet. It could also support age-banded dosing.

Excipient replacement and supply security

Strategic government procurement may favor products with resilient supply chains. A qualified replacement for a vulnerable excipient can be commercially valuable even when it does not produce a visibly different product. Priority targets include:

• Polysorbate 80.
• Sodium benzoate.
• Pharmaceutical-grade sucrose.
• Microcrystalline cellulose.
• Croscarmellose sodium.
• Coating polymers.
• Flavor systems.

The supplier must demonstrate equivalent performance and maintain regulatory documentation suitable for an NDA supplement or manufacturing-change submission.

What patents protect Tembexa formulations and excipient systems?

Tembexa's patent protection is likely to include several layers:

Patent layer	Potential subject matter	Relevance to excipient strategy
Active compound	Brincidofovir and related lipid conjugates	Broadest barrier to competing products using the same active
Composition	Pharmaceutical compositions containing brincidofovir	May cover drug-excipient combinations
Formulation	Oral suspension, tablet, particle-size, or solubilization systems	Directly relevant to alternative excipient systems
Manufacturing	Synthesis, purification, crystallization, or processing	Can restrict supply of non-infringing active ingredient
Method of use	Treatment or prevention of orthopoxvirus infection	Can affect labeling and generic commercialization
Pediatric use	Dosing or administration methods	May limit labeled generic use even where composition claims expire

A replacement excipient is not automatically outside the patent estate. A claim may define the active ingredient and a broad excipient class, a concentration range, a pH range, a particle-size distribution, or a functional result such as improved stability. Conversely, a narrow claim directed to a particular excipient combination may be avoided through a well-designed formulation.

Patent due diligence should review the FDA Orange Book for NDA 214460, issued U.S. patents, terminal disclaimers, patent-term adjustment, patent-term extension, and any relevant reexamination or post-grant proceedings. The FDA Orange Book remains the primary source for patents submitted for listing against the approved product (FDA, 2025a).

When does Tembexa lose exclusivity and what generic entry risks exist?

Tembexa does not have biosimilar risk because brincidofovir is a small molecule and the applicable pathway is an ANDA, not a biosimilar application. Generic entry could occur through:

• Paragraph I certification if no patent is listed.
• Paragraph II certification if a listed patent has expired.
• Paragraph III certification accepting entry after patent expiration.
• Paragraph IV certification alleging that a listed patent is invalid, unenforceable, or not infringed.

The timing of generic entry depends on listed patent expiration, regulatory exclusivity, pediatric exclusivity, litigation, and settlement terms. The product received FDA approval in June 2021. Any five-year new chemical entity exclusivity period would generally be relevant to ANDA submission timing, subject to the product's regulatory classification and statutory exceptions. The exact entry date requires review of the current Orange Book and any later FDA exclusivity updates.

A generic applicant could challenge the tablet, suspension, or both. A suspension applicant would face additional pharmaceutical-equivalence requirements involving particle size, viscosity, redispersibility, preservative content, and dose uniformity.

What is the Orange Book status of Tembexa?

Tembexa is an NDA product listed in the FDA Orange Book under NDA 214460. Orange Book analysis should distinguish between:

• Active ingredient patents.
• Drug product or formulation patents.
• Method-of-use patents.
• Patents that may be listed but have limited practical value against a proposed generic label.
• Regulatory exclusivity separate from patent protection.

The commercial significance of each listing depends on claim scope. A formulation patent covering a specific suspension system may be more relevant to a liquid generic than to a tablet generic. A method-of-use patent may be less effective if a generic applicant uses a permissible carve-out or obtains approval for a narrower indication.

Which companies are challenging Tembexa?

Publicly reported commercial activity has focused more on government procurement and product ownership than on a mature generic challenge landscape. Tembexa was developed and commercialized by Chimerix, with the U.S. government as a major customer through strategic procurement arrangements. Chimerix disclosed a large Biomedical Advanced Research and Development Authority contract connected to brincidofovir supply and development (Chimerix, 2021).

A company-specific Paragraph IV assessment requires current FDA Orange Book entries, ANDA litigation records, and district-court or Federal Circuit filings. No broad biosimilar competition is expected because the product is not a biologic. Generic competition would most likely begin with an oral solid dosage form, followed by a suspension if the market opportunity justifies the additional development cost.

How does Tembexa compare with competing smallpox countermeasures?

Product	Active ingredient	Dosage form	Excipient and commercial distinction
Tembexa	Brincidofovir	Tablet and oral suspension	Oral dosing, pediatric suspension, stockpile use
Tpoxx	Tecovirimat	Capsule and injection	Oral solid and injectable options; different mechanism
ACAM2000	Vaccinia virus	Live-virus vaccine	Vaccine excipient, administration, and safety profile
Jynneos	Modified vaccinia Ankara-Bavarian Nordic	Injectable vaccine	Refrigerated vaccine supply chain and parenteral delivery

Tembexa's commercial advantage is oral administration without the operational requirements of injectable products. Its weakness is formulation complexity in pediatric suspension delivery and the limited routine market for a smallpox-only therapy.

What licensing and manufacturing opportunities exist?

Potential licensing structures include:

• Excipient technology licenses for taste masking or controlled release.
• Co-development agreements for pediatric presentations.
• Contract manufacturing arrangements for suspension filling.
• Government-backed supply agreements.
• Regional commercialization licenses.
• Dual-source manufacturing agreements for critical excipients.
• Packaging and dosing-device partnerships.

Manufacturing barriers include control of brincidofovir particle size, prevention of degradation, low-bioburden liquid processing, validated suspension mixing, and long-term container-closure performance. A formulation partner that can provide a complete package, including excipients, filling, stability, and device integration, has a stronger position than a commodity excipient supplier.

How strong is the Tembexa patent estate?

The estate is commercially strongest where it combines active-ingredient protection with formulation and manufacturing claims. A competing product may need to clear multiple barriers:

1. Use of brincidofovir itself.
2. Pharmaceutical equivalence to the approved dosage form.
3. Listed patents in the Orange Book.
4. Manufacturing-process claims.
5. Method-of-use claims for the approved indication.
6. Government procurement and supply requirements.

Excipient-focused patents are narrower than active-ingredient patents but can delay direct substitution, particularly for the oral suspension. A new formulation may still obtain its own patent protection around taste masking, particle engineering, suspension stability, low-sugar composition, packaging, or dosing devices.

Key takeaways

• Tembexa's most commercially important excipient platform is the 10 mg/mL oral suspension.
• Taste masking, redispersibility, preservative control, and pediatric dosing accuracy are the primary formulation targets.
• Stockpile economics favor room-temperature stability, low logistics burden, dual-source excipients, and integrated dosing systems.
• Small-molecule generic risk exists; biosimilar risk does not.
• A Paragraph IV challenge could target tablets, suspension, or both, but a liquid generic would face greater formulation-development complexity.
• Excipient substitutions must be evaluated against Orange Book-listed formulation patents, composition claims, manufacturing claims, and regulatory comparability requirements.
• The best licensing opportunities involve pediatric reformulation, suspension manufacturing, packaging, dosing devices, and supply-chain resilience.
• Tembexa's limited routine market makes government procurement, preparedness contracts, and strategic supply agreements more important than ordinary retail prescription demand.

FAQs

Can Tembexa be reformulated without changing the active ingredient?

Yes. A reformulation could change excipients, dosage form, flavor, concentration, packaging, or dosing device. The sponsor would need to establish stability, pharmaceutical performance, and regulatory comparability.

What is the best excipient opportunity for a Tembexa competitor?

A pediatric taste-masked suspension with lower administration volume and improved redispersibility is the most commercially differentiated opportunity.

Does Tembexa require a biosimilar application?

No. Brincidofovir is a small molecule. A competing product would generally use the ANDA pathway if it meets generic-drug requirements.

Can a generic Tembexa avoid formulation patents by changing excipients?

Potentially, but only if the revised formulation does not practice the relevant patent claims. Changing one excipient does not avoid claims covering the active ingredient, broad composition ranges, particle characteristics, manufacturing process, or method of use.

Why is packaging important for Tembexa?

Packaging affects shelf life, preservative performance, container adsorption, suspension uniformity, dosing accuracy, and emergency deployment. An integrated bottle-and-syringe system can reduce pediatric dosing errors and improve stockpile usability.

References

1. Chimerix, Inc. (2021). Chimerix announces procurement contract for brincidofovir for the Strategic National Stockpile. Chimerix investor materials.

2. U.S. Food and Drug Administration. (2021a). Tembexa (brincidofovir) prescribing information. NDA 214460.

3. U.S. Food and Drug Administration. (2021b). FDA approves first drug with an indication for treatment of smallpox. FDA.

4. U.S. Food and Drug Administration. (2025a). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

5. U.S. Food and Drug Administration. (2025b). Inactive ingredient database. FDA.